MEDIMMUNE LIMITED

Risk Rating: LOW The company exhibits strong indicators of financial and operational stability, driven primarily by its status as a wholly-owned subsidiary of a larger corporate group (Cambridge Antibody Technology Group Limited). Regulatory compliance is impeccable with no overdue filings, and the company benefits from a long operating history and a strategic location within a premier UK R&D hub. While standalone financial data is limited, the structural backing of the PSC significantly mitigates insolvency risk.

Key Concerns: - Opaque Standalone Financials: The stated share capital is only £3.00, and no detailed balance sheet data (assets, liabilities, reserves) is provided in the available data. This suggests the company is likely funded via intercompany loans rather than share capital, making it impossible to assess standalone solvency or liquidity without the full accounts. - Subsidiary Dependency: With 100% of shares and voting rights held by Cambridge Antibody Technology Group Limited, the company's operational continuity is entirely dependent on the strategic priorities and financial health of its parent entity. A shift in the parent's R&D strategy could impact the subsidiary's future. - Board Complexity and Turnover: The board is unusually large for a private limited company (15 directors), with multiple nationalities and a company secretary. While typical for a major corporate subsidiary, large boards can sometimes lead to complex governance or high director turnover, which warrants monitoring for operational consistency.

Positive Indicators: - Strong Corporate Backing: The PSC (Cambridge Antibody Technology Group Limited) holds over 75% of shares and voting rights and retains the right to appoint and remove directors. This provides implicit financial support and indicates that the entity is a strategic component of a larger, well-capitalized corporate structure. - Excellent Compliance Record: The company files full accounts (not abbreviated or micro-entity), and both its annual accounts and confirmation statements are up to date with no overdue filings. This demonstrates robust administrative governance and transparency. - Strategic Location and Heritage: Operating since 1989, with a previous identity as Cambridge Antibody Technology Limited, the firm is based at the Cambridge Biomedical Campus. This indicates deep roots in the UK life sciences sector and access to top-tier R&D infrastructure and talent.

Due Diligence Notes: - Obtain and review the latest full accounts to analyze the intercompany loan structure, debtor/creditor balances with the parent, and any parent company guarantees. The £3 share capital means the entity's standalone equity is negligible without parent backing. - Conduct a credit and risk assessment on the PSC (Cambridge Antibody Technology Group Limited) and its ultimate parent, as the subsidiary's risk profile is intrinsically linked to the parent's financial health. - Investigate the specific mandates and R&D projects assigned to this entity. As an R&D-focused subsidiary, its value and operational necessity are tied to the success and continuation of its parent's development pipeline.